Taste acuity improvement - patient-reported outcome · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
It is very uncertain whether zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… changes taste acuity improvement - patient-reported outcome compared with placebo (very low certainty).
1 finding from 1 review
Taste acuity improvement - objective outcome (continuous) - taste recognition (cross-over trial) · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
It is very uncertain whether zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… changes taste acuity improvement - objective outcome (continuous) - taste… compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
1 finding from 1 review
Taste acuity improvement - objective outcome (dichotomous) - chronic renal failure · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
Zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… led to higher taste acuity improvement - objective outcome (dichotomous) - chronic… compared with placebo; GRADE not reported.
1 finding from 1 review
Taste acuity improvement - objective outcome (continuous data) · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
It is very uncertain whether zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… changes taste acuity improvement - objective outcome (continuous data) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
It is very uncertain whether zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Taste acuity improvement - objective outcome (dichotomous data) · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
It is very uncertain whether zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… changes taste acuity improvement - objective outcome (dichotomous data) compared with placebo (very low certainty).
1 finding from 1 review
Volatile sulphur compounds (VSC), halimeter · Adults over 18 years with a clinical or self-assessed diagnosis of halitosis, without significant comorbidity (e.g. diabetes) or…
1 finding from 1 review
Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Taste disturbance (severe, > 2 on 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc led to lower taste disturbance (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Xerostomia (severe) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc led to lower xerostomia (severe) compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Oral pain · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc led to lower oral pain (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Disability of oral intake · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc showed no clear difference in disability of oral intake compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Polaprezinc led to lower oral mucositis (moderate to severe) compared with azulene; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Polaprezinc showed no clear difference in oral mucositis (any severity) compared with azulene; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies
Polaprezinc led to lower oral mucositis (severe) compared with azulene; GRADE not reported.
1 finding from 1 review
Cognitive function · cognitively healthy people in mid and late life
1 finding from 1 review
Incidence of dementia or MCI · cognitively healthy people in mid and late life
1 finding from 1 review